On November 25, 2024, QUIA PHARMA AB (publ) (the "Company") disclosed a press release with information that the Company had received a Statement of Reprimand from Nasdaq Stockholm AB expressing the intention of Nasdaq Stockholm AB to refer a disciplinary case concerning the Company to the Disciplinary Committee of Nasdaq Stockholm, requesting the Disciplinary Committee to decide to delist the shares of the Company from Nasdaq First North Growth Market.
On January 22, 2025, Nasdaq Stockholm AB referred the case concerning the Company to the Disciplinary Committee of Nasdaq Stockholm, requesting the Disciplinary Committee to decide to delist the shares of the Company from Nasdaq First North Growth Market.
According to the rules of Nasdaq First North Growth Market, item 6.3.1 (a), an issuer's financial instruments may be given observation status if circumstances exist justifying the removal of the Issuer's Financial Instruments from trading on Nasdaq First North Growth Market pursuant to item 8.2.1.
With reference to the above, Nasdaq Stockholm AB decides that the shares in QUIA PHARMA AB (publ) (QUIA, ISIN code SE0020678159, order book ID 200627) shall be given observation status.
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
